Skip to main content
v2026.11,610 entries · CC-BY 4.0
LAC HealthLaboratory & ResearchLab & research supplies.Reagents, consumables, PPE & instruments — documented, fast, chain-of-custody shipping.Shop lac.us lac.us

Editorial · CASRAI · tech-transfer

UK Spinout Equity Stakes Hit Decade Low, RAEng Reports

The Royal Academy of Engineering’s 2026 Spotlight on Spinouts report finds UK universities’ average spinout equity stake has fallen to 16%, a decade low, down from 22% the year before — with life sciences averaging 20% and hardware 14%, both within the Independent Review’s recommended 10-25% band.

Published 30 Jul 2026· 5 minute read

The Royal Academy of Engineering’s sixth annual Spotlight on Spinouts report, published in 2026, finds that the average equity stake UK universities take in their spinout companies has fallen to 16%, down from 22% the previous year and the lowest level recorded in the decade the report series has been tracking the figure. The report frames the drop as evidence that the 2023 Independent Review of University Spin-out Companies and the sector guidance it produced are now visibly changing institutional behaviour, not just institutional policy documents.

What actually changed

The Independent Review, published in November 2023, recommended that university equity stakes in IP-intensive spinouts (life sciences and similarly deep-tech, patent-heavy ventures) generally fall in the 10-25% range, and 10% or less for less IP-intensive spinouts such as software. Those figures were drawn substantially from the TenU University Spinout Investment Terms (USIT) Guide, a benchmarking framework built by a consortium of UK and international technology transfer offices working with venture investors, law firms, and professional associations. The Review’s core argument was that stakes running well above that band — institutions historically took 30-50% or more in some cases — were making UK spinouts structurally less attractive to the follow-on venture capital they need to scale, without a corresponding benefit to the university’s own return.

Three years on, the 2026 Spotlight report is the clearest sector-wide evidence yet that the recommendation is being adopted rather than merely acknowledged. According to the report, average equity stakes are also more consistent across the sector than in prior years, suggesting the 10-25%/10%-or-less guidance is functioning as a genuine norm rather than a range a handful of well-resourced technology transfer offices (TTOs) happen to already hit.

The sector breakdown

The headline 16% figure is a sector-wide average, and the report’s sector-level detail is arguably the more useful number for anyone actually negotiating a term sheet. For deals struck in 2024-2025, the report puts the average university stake at 20% in life sciences spinouts and 14% in hardware spinouts — both comfortably inside the Independent Review’s recommended bands for their respective IP-intensity categories. That life sciences sits toward the upper-middle of its 10-25% band while hardware sits below the midpoint of the same band is broadly consistent with how the Review’s guidance was written: life sciences ventures typically carry more foundational, patent-protected university IP at spinout than a hardware company built more around know-how and design, so a somewhat higher stake in that band is expected rather than anomalous.

The report does not, in the sources available at time of writing, break out a comparable current-year average specifically for software-only spinouts, which the Independent Review treats as its own lower (10%-or-less) category.

Funding activity alongside the equity trend

The lower average stake has coincided with, not come at the expense of, strong headline funding activity: the report records UK spinouts raising £2.6bn in 2024, up 38% year-on-year, even as broader UK venture funding contracted. The report also notes continued concentration of spinout activity in the “Golden Triangle” of Oxford, Cambridge and London, alongside evidence of growth in spinout formation elsewhere in the UK. Read together, the funding and equity trends support the report’s central claim: TTOs taking smaller founding stakes has not obviously come at the cost of the university’s absolute return, because deal volume and deal value have both been strong over the same period. Longer-run causation is harder to establish from a single annual report, and the Spotlight series itself is best read as an evolving multi-year time series rather than a one-off snapshot.

What this means for TTOs and founders negotiating today

For a technology transfer office setting a term sheet in 2026, the practical implication is that 16% sector-wide, or roughly 20% for life sciences and 14% for hardware, is now the realistic market reference point — not a theoretical floor from a three-year-old policy document. An institution proposing a stake meaningfully above those figures should expect a founder or investor to point to this report as evidence of where the market has actually settled. Conversely, founders and investors should not assume every TTO has converged on the mean: the Independent Review’s guidance remains a recommended band, not a mandate, and individual institutional policy, the specific IP position at spinout, and the deal’s other terms (founder vesting, anti-dilution provisions, board rights) all still shape where a given negotiation lands within or around that band. CASRAI’s guide on how founders and TTOs set the initial equity stake covers that underlying negotiation mechanics in more depth; this piece focuses specifically on what the new 2026 data shows about where the sector has actually landed.

Frequently asked questions

What is the Spotlight on Spinouts report?

It is the Royal Academy of Engineering’s annual quantitative and qualitative analysis of UK university spinout activity, now in its sixth edition, covering equity stakes, deal volumes, funding raised, and sector and regional distribution of spinout companies.

Is 16% now a mandated maximum equity stake for UK universities?

No. The 10-25%/10%-or-less bands originate from the 2023 Independent Review and the TenU USIT Guide as recommended guidance, not a legal or funding-conditional requirement. The 16% figure is a sector-wide observed average across deals in the reporting period, not a ceiling any individual institution is bound by.

Why do life sciences spinouts see higher average stakes than hardware spinouts?

Life sciences ventures typically spin out with more extensive, patent-protected university-owned IP as their core asset, which the Independent Review’s own framework treats as justifying a higher stake within the recommended band than a hardware or software venture built more around know-how, design, or a narrower IP position.

Where can I read the full report?

The Royal Academy of Engineering publishes the Spotlight on Spinouts report series on its own site, alongside supporting sector and regional data.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →